RSS feed

Publications (original articles or review articles) published in 2024 from OUS - Molecular Genetic Studies of Breast and Ovarian Cancer (Russnes)

9 publications found

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, Stenzinger A, Rosenquist R, PCM4EU consortium (2024)
High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond
J Intern Med, 295 (6), 785-803
DOI 10.1111/joim.13785, PubMed 38698538

Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13656, PubMed 38671580

Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
[Raising the quality of cancer treatment]
Tidsskr Nor Laegeforen, 144 (1)
DOI 10.4045/tidsskr.23.0740, PubMed 38258713

Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Otterlei Fjørtoft M, Huse K, Rye IH (2024)
The Tumor Immune Microenvironment in Breast Cancer Progression
Acta Oncol, 63, 359-367
DOI 10.2340/1651-226X.2024.33008, PubMed 38779867

Stålberg SM, Silwal-Pandit L, Bastani NE, Nebdal DJH, Lingjærde OC, Skålhegg BS, Kure EH (2024)
Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease
BMC Cancer, 24 (1), 555
DOI 10.1186/s12885-024-12320-8, PubMed 38702616

Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H et al. (2024)
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
Acta Oncol, 63, 385-391
DOI 10.2340/1651-226X.2024.34791, PubMed 38779910